/ /

  • linkedin
  • Increase Font
  • Sharebar

    Identifying glaucoma-related visual function loss

    Early findings favorable for novel, portable visual evoked potential technology



    Diagnostic evaluation

    Initial evaluation of the technology was performed using a prototype device in a case-controlled study that included 62 eyes of 33 glaucoma patients and 30 eyes of 17 healthy individuals. Glaucoma patients had relatively mild disease (average mean deviation ~–4 dB), and 11 of the 62 glaucomatous eyes had preperimetric disease.

    For the testing, the field of view was divided into 20 sectors, each flickering at a specific frequency. Global and sectoral mfSSVEPs were compared with global and sectoral SAP parameters.

    Results showed the area under the receiver operating characteristic (ROC) curve for the brain-computer interface was 0.924, and it was significantly larger (better performance) than the SAP parameters used as comparators (mean deviation, 0.81; mean sensitivity, 0.80; pattern standard deviation, 0.77), Dr. Medeiros noted.

    Although eyes with preperimetric glaucoma had no evidence of visual function loss on SAP, they exhibited decreased mfSSVEP responses compared with healthy controls (0.280 versus 0.334). Sectors of visual function loss with the device corresponded with those identified on SAP. Thinner measurements on spectral domain-optical coherence tomography also corresponded to lower amplitudes on the mfSSVEP, he added.

    The technology has potential applications beyond assessment of glaucomatous visual function loss, he noted.

    “The device could potentially be used for assessing higher cognitive functioning by creating virtual reality tasks and monitoring brain activity through EEG,” Dr. Medeiros said.


    Felipe A. Medeiros, MD, PhD
    e: [email protected]
    This article was adapted from Dr. Medeiros’ presentation at the 2017 meeting of the American Academy of Ophthalmology.
    Dr. Medeiros is a co-founder of nGoggle Inc. Dr. Medeiros is also a consultant and has received research support from Carl Zeiss Meditec and Heidelberg Engineering.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results